跳至主要内容
临床试验/NCT07680751
NCT07680751尚未招募不适用

European Cystinosis Cohort 2

Institut National de la Santé Et de la Recherche Médicale, France1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2026年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
250
试验地点
1
主要终点
Long-term clinical disease progression in cystinosis

研究概览

简要总结

This European observational cohort follows patients with cystinosis, a rare lysosomal storage disease caused by CTNS mutations leading to cystine accumulation and multisystem involvement. It aims to describe the long-term clinical course under current treatments, focusing on renal and extra-renal complications, survival, and quality of life. It also evaluates treatment effects and explores biomarkers, including inflammatory markers, with biobanking for future research.

详细描述

Cystinosis is a rare autosomal recessive lysosomal storage disorder caused by pathogenic variants in the CTNS gene encoding cystinosin, the lysosomal cystine transporter. The resulting defect leads to progressive intralysosomal cystine accumulation, causing multisystem cellular dysfunction and progressive organ involvement. The disease typically presents in infancy with renal Fanconi syndrome and progresses to chronic kidney disease and, without cystine-depleting therapy, end-stage kidney disease in childhood. With advances in cysteamine therapy, renal replacement therapy, and kidney transplantation, survival has improved significantly, resulting in a chronic multisystem disease affecting both pediatric and adult populations.

At the cellular level, cystinosis involves lysosomal dysfunction, impaired autophagy, oxidative stress, dysregulated endolysosomal trafficking, and chronic inflammatory activation. Macrophage activation and inflammatory pathways are increasingly recognized as contributors to disease progression.

This study is conducted within the RaDiCo-ECYSCO platform, a European rare disease cohort designed for standardized longitudinal data collection in patients with cystinosis followed in expert reference centers. ECYSCO2 is the continuation of the original ECYSCO cohort and extends long-term follow-up and harmonized clinico-biological data collection.

The cohort is multicentric and includes specialized centers across Europe. It is embedded in routine clinical care, and data collection is non-interventional and based on standard follow-up procedures without modification of patient management.

Data are collected using standardized electronic case report forms (eCRFs) within the REDCap® platform of the RaDiCo information system. The system supports full data lifecycle management including data capture, validation, monitoring, and statistical analysis. Source data are defined as medical records, laboratory reports, imaging data, and patient questionnaires (paper or electronic). Investigators are responsible for ensuring consistency between source documents and eCRF entries.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

性别
All
接受健康志愿者

入选标准

  • Confirmed diagnosis of cystinosis based on leukocyte cystine measurement, presence of corneal cystine crystals, and/or molecular genetic diagnosis
  • Signed informed consent obtained from the patient or legal representative

排除标准

  • Patients unable to provide informed consent or without a legal representative when required
  • No other specific exclusion criteria; patients with associated diseases may be included

结局指标

主要结局

Long-term clinical disease progression in cystinosis

时间窗: Through study completion, an average of 6 years

Evaluation of long-term disease progression in patients with cystinosis, including renal function (eGFR, renal replacement therapy), ocular involvement, endocrine manifestations, neurological abnormalities, muscular and gastrointestinal complications, and survival. Additional data include current treatments and CTNS genotyping.

次要结局

  • Quality of life in patients with cystinosis (adults)(Through study completion, an average of 6 years)
  • Quality of life in patients with cystinosis (children)(Through study completion, an average of 6 years)
  • Treatment adherence in patients with cystinosis(Through study completion, an average of 6 years)
  • Renal function assessment in patients with cystinosis(Through study completion, an average of 6 years)
  • Ocular manifestations assessment in patients with cystinosis(Through study completion, an average of 6 years)
  • Endocrine manifestations assessment in patients with cystinosis(Through study completion, an average of 6 years)
  • Neurological, gastrointestinal, muscular and dermatological manifestations assessment in patients with cystinosis(Through study completion, an average of 6 years)
  • Cystinosis treatment exposure(Through study completion, an average of 6 years)
  • Long-term safety and adverse events of treatments(Through study completion, an average of 6 years)
  • Biological sample collection and biomarker analysis(Baseline and every 2 years during follow-up, and at disease events)

研究者

发起方
Institut National de la Santé Et de la Recherche Médicale, France
申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

尚未招募
2 期
一项在中度至重度活动性溃疡性结肠炎和中度至重度活动性克罗恩病受试者中进行口服 Zasocitinib(TAK279)的长期安全性和耐受性的开放性扩展研究中度至重度活动性溃疡性结肠炎和中度至重度活动性克罗恩病
CTR20253581Takeda Development Center Americas, Inc./ 武田(中国)国际贸易有限公司/ Serán BioScience, LLC/ Almac Clinical Services LLC
Unknown
不适用
CRISPLD2 在评估脓毒症预后方面的价值
ChiCTR-OCC-11001244上海市公共卫生优秀学科带头人培养计划(08GWD21)250
招募中
3 期
一项在儿科受试者中开展的古塞奇尤单抗延长期研究(备注:本研究药物尚未在中国申报儿童克罗恩病、幼年银屑病关节炎适应症临床试验,目前仅开展 CNTO1959PUC3001(一项在中重度活动性溃疡性结肠炎儿科受试者中评价古塞奇尤单抗的疗效、安全性和药代动力学的 III 期、随机、开放性诱导治疗、双盲维持治疗、平行组、多中心研究)。本研究仅对儿童溃疡性结肠炎适应症进行评价。)克罗恩病、溃疡性结肠炎或幼年银屑病关节炎
CTR20250192Janssen Research & Development, LLC/ 强生(中国)投资有限公司/ Cilag AG/ Janssen R&D, a Division of Janssen Pharmaceutica, NV; Fisher Clinical Services; Fisher Clinical Services GmbH; Catalent Germany Schorndorf GmbH; Catalent Pharma Solutions, LLC
Unknown
不适用
探索高剂量二联疗法在难治性幽门螺杆菌感染中的治疗价值临床研究方案
ChiCTR2200057248SCI 论文基金经费卡496
招募中
Unknown
王馨珂医师:该研究的伦理审批文件未上传,请尽快上传。 克罗恩病伴肛瘘形成的致病基因及菌群的研究
ChiCTR1900027370研究者发起的研究50